CLOVER LEAF CAP CORP RT Stock (OTC: CLOER)

Latest news for CLOVER LEAF CAP CORP RT (OTC:CLOER) Stock

CLOVER LEAF CAP CORP RT

Needham analyst David Saxon maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and raises the price target from $149 to $176.

News

Price Target

Analyst Ratings

GKOS

Needham Maintains Buy on Glaukos, Raises Price Target to $176

<a href="https://x.com/BillAckman/status/1892912458840547554" title="https://x.com/BillAckman/status/1892912458840547554">https://x.com/BillAckman/status/1892912458840547554</a>

Hedge Funds

General

Investor Bill Ackman, In Response To Wall Street Journal Report Of DoJ Investigation Into United Health's Medicare Billing Practices, Posted on X He Would Avoid The Stock

Needham analyst James Ricchiuti maintains Universal Display (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLED#NASDAQ">OLED</a>) with a Buy and lowers the price target from $215 to $170.

OLED

Needham Maintains Buy on Universal Display, Lowers Price Target to $170

HC Wainwright &amp; Co. analyst Ed Arce reiterates Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) with a Neutral and maintains $5.5 price target.

Reiteration

ARDX

HC Wainwright & Co. Reiterates Neutral on Ardelyx, Maintains $5.5 Price Target

United States Cellular (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USM#NYSE">USM</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.05) by 200 percent. This is a 68.75 percent decrease over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $970.00 million which beat the analyst consensus estimate of $965.87 million by 0.43 percent. This is a 3.00 percent decrease over sales of $1.00 billion the same period last year.

Earnings

Earnings Beats

United States Cellular Q4 2024 GAAP EPS $0.05 Beats $(0.05) Estimate, Sales $970.00M Beat $965.87M Estimate

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Buy and maintains $180 price target.

RGEN

HC Wainwright & Co. Reiterates Buy on Repligen, Maintains $180 Price Target

NIXX

Nixxy Enters Telecommunications And Data Sectors With AI Integration And Software Asset Purchase, Targets $5M Monthly Revenue In Q2

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">TDS Telecom</td>
<td colspan="1" rowspan="1">2025 Estimated Results</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Actual Results for the Year Ended December 31, 2024</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(Dollars in millions)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total operating revenues</td>
<td colspan="1" rowspan="1">$1,030-$1,070</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$1,061</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted OIBDA (Non-GAAP)</td>
<td colspan="1" rowspan="1">$310-$350</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$340</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA&nbsp;(Non-GAAP)</td>
<td colspan="1" rowspan="1">$320-$360</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$350</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Capital expenditures</td>
<td colspan="1" rowspan="1">$375-$425</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$324</td>
</tr>
</tbody>
</table>
</figure>

Guidance

Telephone and Data Systems' TDS Telecom Segment Expects FY25 Operating Revenue Of $1.03B-$1.07B Vs $1.06B YoY, Capex Of $320M-$360M Vs $350M YoY

Sunstone Hotel Investors Expects FY25 Adjusted FFO Per Share Of $0.86 - $0.98, Est $0.97

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Buy and maintains $28 price target.

BNTC

HC Wainwright & Co. Reiterates Buy on Benitec Biopharma, Maintains $28 Price Target

NCTY

The9 Forms Joint Venture With Chengdu Qing Cheng Network To Expand Mobile Game Operations In China's Sinking Market

Canaccord Genuity analyst Kyle Mikson maintains Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Hold and raises the price target from $165 to $170.

Canaccord Genuity Maintains Hold on Repligen, Raises Price Target to $170

VMAR

Vision Marine Technologies Announced That Its Board Of Directors Has Approved Stock Repurchase Program Authorizing The Repurchase Of Up To 5% Of Company's Issued And Outstanding Common Shares As Of Today

Mizuho analyst Vijay Rakesh maintains Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) with a Neutral and raises the price target from $11 to $13.

RIVN

Mizuho Maintains Neutral on Rivian Automotive, Raises Price Target to $13

Sunstone Hotel Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHO#NYSE">SHO</a>) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.14 by 14.29 percent. This is a 15.79 percent decrease over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $214.77 million which beat the analyst consensus estimate of $211.17 million by 1.70 percent. This is a 2.03 percent decrease over sales of $219.22 million the same period last year.

Sunstone Hotel Invts Q4 2024 Adjusted FFO Per Share $0.16 Beats $0.14 Estimate, Sales $214.77M Beat $211.17M Estimate

Earnings Misses

Telephone and Data Q4 2024 Adj. EPS $(0.09), Sales $1.240B Miss $1.254B Estimate

Canaccord Genuity analyst Kyle Rose maintains Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Buy and raises the price target from $304 to $324.

PODD

Canaccord Genuity Maintains Buy on Insulet, Raises Price Target to $324

HC Wainwright &amp; Co. analyst Yi Chen maintains Bausch &amp; Lomb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) with a Buy and lowers the price target from $23 to $20.

BLCO

HC Wainwright & Co. Maintains Buy on Bausch & Lomb, Lowers Price Target to $20

Under the terms of the agreement, bluebird stockholders will receive $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right if bluebird's current product portfolio achieves $600 million in net sales in any trailing 12-month period prior to or ending on December 31, 2027, for a potential total value of up to $9.84 per share in cash, subject to the tender of a majority of the outstanding shares of bluebird, receipt of applicable regulatory approvals, and other customary closing conditions.

BLUE

bluebird bio Agrees To Be Acquired By Carlyle And SK Capital For Potential Total Value Of Up To $9.84 Per Share In Cash

Piper Sandler analyst Brent Bracelin reiterates Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) with a Overweight and maintains $53 price target.

Comments

CLOVER LEAF CAP CORP RT

News

Latest news for CLOVER LEAF CAP CORP RT (OTC:CLOER) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga